These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 35383532)

  • 1. Novel dual glucagon-like peptide-1/ glucose-dependent insulinotropic polypeptide receptor agonist attenuates diabetes and myocardial injury through inhibiting hyperglycemia, inflammation and oxidative stress in rodent animals.
    Wang Y; Cai F; Li G; Tao Y
    Bioengineered; 2022 Apr; 13(4):9184-9196. PubMed ID: 35383532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.
    Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA
    Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Atageldiyeva KK; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Diabetologia; 2016 Mar; 59(3):533-41. PubMed ID: 26693710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals.
    Cui J; Shang A; Wang W; Chen W
    Life Sci; 2020 Nov; 260():118339. PubMed ID: 32841660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of glucagon-like peptide-1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamycin complex 1/p70 ribosomal protein S6 kinase pathway in diabetes mellitus.
    Wang D; Jiang L; Feng B; He N; Zhang Y; Ye H
    J Diabetes Investig; 2020 Jan; 11(1):39-51. PubMed ID: 31199578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatoprotective potential of alpha-lipoic acid against gliclazide-induced liver injury in high-glucose-exposed human liver cells and experimental type 2 diabetic rats.
    Dugbartey GJ; Atule S; Alornyo KK; Adams I
    Biochem Pharmacol; 2024 Sep; 227():116447. PubMed ID: 39038553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
    Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
    Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
    Gault VA; Bhat VK; Irwin N; Flatt PR
    J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
    Wu Y; Ji T; Lv J; Wang Z
    Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Wang Y; Zheng X; Li L; Wang H; Chen K; Xu M; Wu Y; Huang X; Zhang M; Ye X; Xu T; Chen R; Zhu Y
    Food Nutr Res; 2020; 64():. PubMed ID: 33061882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streptozotocin-induced diabetic cardiomyopathy in rats: ameliorative effect of PIPERINE via Bcl2, Bax/Bcl2, and caspase-3 pathways.
    Wang Y; Sun H; Zhang J; Xia Z; Chen W
    Biosci Biotechnol Biochem; 2020 Dec; 84(12):2533-2544. PubMed ID: 32892714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors.
    Spielman LJ; Gibson DL; Klegeris A
    Eur J Cell Biol; 2017 May; 96(3):240-253. PubMed ID: 28336086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMGCS2 silencing attenuates high glucose-induced in vitro diabetic cardiomyopathy by increasing cell viability, and inhibiting apoptosis, inflammation, and oxidative stress.
    Chen D; Ruan X; Liu Y; He Y
    Bioengineered; 2022 May; 13(5):11417-11429. PubMed ID: 35506308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SIRT6‑specific inhibitor OSS‑128167 exacerbates diabetic cardiomyopathy by aggravating inflammation and oxidative stress.
    Huang Y; Zhang J; Xu D; Peng Y; Jin Y; Zhang L
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
    Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
    Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
    Ma T; Lu W; Wang Y; Qian P; Tian H; Gao X; Yao W
    Eur J Pharmacol; 2022 Jan; 914():174635. PubMed ID: 34800466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoliquiritigenin attenuates diabetic cardiomyopathy via inhibition of hyperglycemia-induced inflammatory response and oxidative stress.
    Gu X; Shi Y; Chen X; Sun Z; Luo W; Hu X; Jin G; You S; Qian Y; Wu W; Liang G; Wu G; Chen Z; Chen X
    Phytomedicine; 2020 Nov; 78():153319. PubMed ID: 32950951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.